

+

Approved for use through 10/31/2002. OMB 061-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Complete if Known

Application Number	09/995,633
Filing Date	November 29, 2001
First Named Inventor	Dennis JONES
Group Art Unit	1614
Examiner Name	Kevin Weddington
Attorney Docket Number	38545-0014

(use as many sheets as necessary)

Sheet	1	of	9
-------	---	----	---

[illegible][illegible]

40-Verdachte

3-1302

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.**

Please type a plus sign (+) inside this box → ☐

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0631-00031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 2 of 9

Complete if Known

Application Number	09/995,633
Filing Date	November 29, 2001
First Named Inventor	Dennis JONES
Group Art Unit	1614
Examiner Name	Kevin Weddington
Attorney Docket Number	38545-0014

RECEIVED
FEB 20 2002
PCT CENTER 1600/2900

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
kw	A05	BEEMAN et al., J. Econ. Entomol, 71(6): 859-861, 1978	
	A06	DAVENPORT et al., Physiol. Entomol, 9(3): 269-274, 1984	
	A07	HOSODA et al., Yakugaku Zasshi, 111(3) 188-192, 1991	
	A08	HUANG et al., Life Sciences, 57(22): 2011-2020, 1995	
	A09	JIA et al., Bulletin of Human Medical College, 8:267-271, 1983	
	A10	KINOSHITA et al., Shoyakugaku Zasshi, 33(3): 146-149, 1979	
	A11	NAMBA et al., Shoyakugaku Zasshi, 39(1): 52-62, 1985	
	A12	ZHAO et al., Chinese Medical Journal, 102(2): 91-93, 1989	
	A13	FONT QUER, P., (1982), "Plantas Medicinales; el Dioscorides renovado", pgs. 95-97, 435438, Editorial Labor S.A., Madrid	
	A14	ROED, P., et al., Helsingor-slankepill. En kontrolleret klinisk undersogelse i almen praksis. Ugeskr. Laeger., 142, 1491-1495	
kw	A15	DIALOG: Chapman & Hall Chemical Database 1989/Nov., "2-Methylamino-1-phenyl-1-propanol"	

Examiner
Signature

Kevin Weddington

Date
Considered

31-13-02

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box →



PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-003

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 3 of 9

Complete if Known

Application Number	09/995,633
Filing Date	November 29, 2001
First Named Inventor	Dennis JONES
Group Art Unit	1614
Examiner Name	Kevin Weddington
Attorney Docket Number	38545-0014

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
KW	A16	DIALOG: The Merck Index Online (SM) 1984, 1985, 1992, "Norpseudoephadrine"	
	A17	DIALOG: The Merck Index Online (SM) 1984, 1985, 1992, "Ephedrine"	
	A18	"Ephedra" from <u>Encyclopedia of Herbs</u> , C. Kowalchik and W.H. Hylton, eds. (Rodale Press: Emmaus, Penn.), 1987, p. 184	
	A19	DULLO et al., <i>Nutrition</i> , 5(1): 7-9, Jan/Feb, 1989	
	A20	GERARD, J., <u>The Herbal or General History of Plants</u> , pages 1116-1117, published 1633, reissued 1975, Dover Publications, Inc., New York	
	A21	JONKERKO, K., et al., <i>Aliment. Pharmacol. Therap.</i> , 5:413-418, 1991	
	A22	QUAADE, F., et al., <i>Ugeskr Laeger</i> , 154/18: 1258-1263, April 1992	
	A23	TYLER, V.E., <u>The Honest Herbal</u> , pages 151-152, George F. Stickley Company, Philadelphia, PA	
	A24	HALMAN, D.S., <i>Muscular Development</i> , pgs. 122-125	
	A25	HEDREI, P., et al., application for Student Research Day, Dec. 3, 1997, Abstract	
lw	A26	ARNER, p., "Adenosine, prostaglandins and phosphodiesterase as targets for obesity", <i>International Journal of Obesity</i> (1993) 17 (Suppl. 1), S57-S59	

Examiner
Signature

Kevin Weddington

Date

Considered

3-13-02

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box →



PTO/SB/08A (08-09)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 4 of 9

Complete if Known

Application Number	09/995,633
Filing Date	November 29, 2001
First Named Inventor	Dennis JONES
Group Art Unit	1614
Examiner Name	Kevin Weddington
Attorney Docket Number	38545-0014

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
kw	A27	ASTRUP, A., "Thermogenesis in human brown adipose tissue and skeletal muscle induced by sympathomimetic stimulation", <i>Acta Endocrinologica</i> (1986) 112 (Suppl. 278), pp. 2-32	
	A28	ASTRUP, A., et al., "Enhanced thermogenic responsiveness during chronic ephedrine treatment in man", <i>The American Journal of Clinical Nutrition</i> (1985) 42: 83-94	
	A29	ASTRUP, A., et al., "The Effect of Chronic Ephedrine Treatment on Substrate Utilization, the Sympathoadrenal Activity, and Energy Expenditure During Glucose-Induced Thermogenesis in Man", <i>Metabolism</i> (1986) 35: 260-265	
	A30	ASTRUP, A., et al., "Thermogenic, Metabolic, and Cardiovascular Effects of a Sympathomimetic Agent, Ephedrine", <i>Current Therapeutic Research</i> (1990) 48, No. 6, pp. 1087-1100.	
	A31	ASTRUP, A., et al., "Caffeine: a double-blind, placebo-controlled study of its thermogenic, metabolic, and cardiovascular effects in healthy volunteers", <i>The American Journal of Clinical Nutrition</i> (1990) 51:759-67	
	A32	ASTRUP, A., et al., "The effect and safety of an ephedrine/caffeine compound compared to ephedrine, caffeine and placebo in obese subjects in an energy restricted diet. A double	
	A33	ASTRUP, A., et al., "The Effect of Ephedrine/Caffeine Mixture on Energy Expenditure and Body Composition in Obese Women", <i>Metabolism</i> (1992) 41: No. 7, pp. 686-688	
	A34	ASTRUP, A., et al., "Ephedrine and Weight Loss", <i>International Journal of Obesity</i> (1992) 16:715	
	A35	Astrup, A., et al., "Pharmacology of thermogenic drugs", <i>The American Journal of Clinical Nutrition</i> (1992) 55:246S-8S	
kw	A36	ASTRUP, A., et al., "Thermogenic, metabolic, and cardiovascular responses to ephedrine and caffeine in man", <i>International Journal of Obesity</i> (1993) 17 (Suppl. 1), pp. S41-S43	

Examiner Signature

Kevin Weddington

Date

Considered


3-13-02

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

RECEIVED
FEB 20 2002
PTO CENTER 1600/2900



Please type a plus sign (+) inside this box →



PTO/SB/08A (08-17)

Approved for use through 10/31/2002. OMB 0651-0047

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 5 of 9

Complete if Known

Application Number	09/995,633
Filing Date	November 29, 2001
First Named Inventor	Dennis JONES
Group Art Unit	1614
Examiner Name	Kevin Weddington
Attorney Docket Number	38545-0014

RECEIVED
FEB 20 2002
1600/2900

RECEIVED

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published..	T ²
lw	A37	BOWN, D., <i>Encyclopedia of Herbs & Their Uses</i> (1995), pp. 108-109, 123	
	A38	Breum, L. et al., "Comparison of an ephedrine/caffeine combination and dexfenfluramine in the treatment of obesity. A double-blind multi-center trial in general practice", <i>International Journal of Obesity</i> (1994) 18(2):99-103	
	A39	BUEMANN, B., et al., "The effect of ephedrine plus caffeine on plasma lipids and lipoproteins during a 4.2 MJ/day diet", <i>International Journal of Obesity</i> (1994) 18:329-332	
	A40	COURT, J. M., et al., "Effect of ephedrine in ketotic hypoglycaemia", <i>Archives of Disease in Childhood</i> (1974) 49: 63-65	
	A41	DALY, P.A., et al., "Ephedrine, caffeine and aspirin: safety and efficacy for treatment of human obesity", <i>International Journal of Obesity</i> (1993) 17 (Suppl. 1), pp. S73-S78	
	A42	DULLOO, A.G., et al., "The Thermogenic Properties of Ephedrine/Methylxanthine Mixtures: Human Studies", <i>International Journal of Obesity</i> (1986) 10:467-481	
	A43	DULLOO, A.G., et al., "Aspirin as a promoter of ephedrine-induced thermogenesis: potential use in the treatment of obesity", <i>The American Journal of Clinical Nutrition</i> (1987) 45:564-9	
	A44	DULLOO, A.G., et al., "Peripheral mechanisms of thermogenesis induced by ephedrine and caffeine in brown adipose tissue", <i>International Journal of Obesity</i> (1991) 15:317-326	
	A45	DULLOO, A.G., et al., "Ephedrine, xanthines and prostaglandin-inhibitors: actions and interactions in the stimulation of thermogenesis", <i>International of Journal of Obesity</i> (1993) 17 (Suppl. 1) pp. S35-S40	
	A46	Facts and Comparisons, A Wolters Kluwer Company, <i>Drug Facts and Comparisons</i> (1995 edition), pp. 962-993	
lw	A47	GAHART, B.L., RN, "Ephedrine Sulfate", <i>Intravenous Medications - a handbook for nurses and other allied health personnel</i> (1985) 4 th Edition, pp. 200-201	

Examiner Signature	<i>lw. Weddington</i>	Date Considered	3-13-02
--------------------	-----------------------	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

+

Please type a plus sign (+) inside this box



PTO/SB/08A (08-00)

Approved for use through 10/31/2002. P.O. Box 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 6 of 9

Complete if Known

Application Number	09/995,633
Filing Date	November 29, 2001
First Named Inventor	Dennis JONES
Group Art Unit	1614
Examiner Name	Kevin Weddington
Attorney Docket Number	38545-0014

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS



Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
W	A48	GEISSLER, C.A., "Effects of weight loss, ephedrine and aspirin on energy expenditure in obese women", <i>International Journal of Obesity</i> (1993) 17 (Suppl. 1), pp. S45-S48	
	A49	GERARD, J., <i>The Herball, or, General Historie of Plantes</i> (1597), 2 pages	
	A50	GOVONI, L.E., Ph.D., RN, et al., "Ephedrine/Ephedrine Sulfate", <i>Drugs and Nursing Implications</i> (1985) 5 th Edition, pp. 496-499	
	A51	GRIEVE, M., "Ephedra", "Lemon", "Lime Fruit" and "Sweet Orange", <i>A MODERN HERBAL - The Medicinal, Culinary, Cosmetic and Economic Properties, Cultivation and Their Modern Scientific Uses</i> (1992), Revised Edition 1973, pp. 286, 474-76, 485, 601-2	
	A52	HOPKINS, D.F.C., et al., "Effective Treatment of Insulin-Induced Edema Using Ephedrine", <i>Diabetes Care</i> (1993) 16, No. 7, pp. 1026-28	
	A53	HUANG, K.C., "Antishock Herbs", "Stomachic and 'Wind'-Dispelling Herbs" and "Other Stomachics and 'Wind'-Dispelling Agents", <i>The Pharmacology of Chinese Herbs</i> (1993), pp. 107-8, 173, 177	
	A54	JONES, D. et al., "Use of Herbs Containing Natural Source Ephedrine Alkaloids in Weight Loss Programmes", <i>International Journal of Obesity</i> (1993), 17 (Suppl. 1), p. S81	
	A55	KAATS, G.R., et al., "Effects of a Multiple Herbal Formulation on Body Composition, Blood Chemistry, Vital Signs, and Self-Reported Energy Levels & Appetite Control", <i>International Journal of Obesity</i> (1994) 18 (Suppl. 2), pp. 145	
	A56	CARR, A., et al., "Ephedra", <i>Rodale's Illustrated Encyclopedia of Herbs</i> , (1987) p. 184	
	A57	KRIEGER, D.R., et al., "Ephedrine, Caffeine and Aspirin Promote Weight Loss in Obese Subjects", <i>Trans. Assoc. Am. Phys.</i> (1990) 103:307-12	
W	A58	LANDSBERG, M.D., et al., "Sympathoadrenal activity and obesity: physiological rationale for the use of adrenergic thermogenic drugs", <i>International Journal of Obesity</i> (1993) 17 (Suppl. 1), pp. S29-S34	

Examiner Signature	<i>Kevin Weddington</i>	Date Considered	3-12-02
--------------------	-------------------------	-----------------	---------

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



Please type a plus sign (+) inside this box



PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0551-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 7 of 9

Complete if Known

Application Number	09/995,633
Filing Date	November 29, 2001
First Named Inventor	Dennis JONES
Group Art Unit	1614
Examiner Name	Kevin Weddington
Attorney Docket Number	38545-0014

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
ke	A59	LEWIS, W.H., et al., "Antiarrhythmic Drugs", "Plants Used to Relieve Toothache", "Phylogenetic Group 8 Myrtales" and "Antidiarrheal Agents", <i>Medical Botany - Plants Affecting Man's Health</i> (1977), pp. 189-190, 250-251, 254-255, 287	
	A60	LOWE, F.C., MD, et al., "Placebo-Controlled Study of Oral Terbutaline and Pseudoephedrine in Management of Prostaglandin E1-Induced Prolonged Erections", <i>Urology</i> (1993) 42, No. 1, pp. 51-54	
	A61	MALCHOW-MOLLER, A., et al., "Ephedrine as an anorectic: the story of the 'Elsinore pill'", <i>International Journal of Obesity</i> (1981) 5:183-187	
	A62	WEATHERALL, D.J., et al., "The Autonomic Nervous System", <i>Oxford Textbook of Medicine</i> (1983), Vol. 2, Section 13Index, pp. 21.22-21.23	
	A63	MOLNAR, D., "Effects of ephedrine and aminophylline on resting energy expenditure in obese adolescents", <i>International Journal of Obesity</i> (1993) 17 (Suppl. 1), S49-S52	
	A64	HIEBLE, J.P., et al., "Pharmacology of the Sympathetic Nervous System", <i>Principles of Pharmacology - Basic Concepts & Clinical Applications</i> (1995), pp. 122-144	
	A65	NIELSEN, B., et al., "Effect of physical training on thermogenic responses to cold and ephedrine in obesity", <i>International Journal of Obesity</i> (1993) 17: 383-390	
	A66	PASQUALI, R., et al., "A Controlled Trial Using Ephedrine in the Treatment of Obesity", <i>International Journal of Obesity</i> (1985) 9: 93-98	
	A67	PASQUALI, R., et al., "Does Ephedrine Promote Weight Loss in Low-Energy-Adapted Obese Women?", <i>International Journal of Obesity</i> (1987) 11:163-168	
	A68	PASQUALI, R., et al., "Thermogenic Agents in the Treatment of Human Obesity Preliminary Results", <i>International Journal of Obesity</i> (1987) 11 (Suppl. 3), pp. 23-26	
w	A69	PASQUALI, R., et al., "Effects of chronic administration of ephedrine during very-low-calorie diets on energy expenditure, protein metabolism and hormone levels in obese subjects", <i>Clinical Science</i> (1992) 82, pp. 85-92	

Examiner Signature

Kevin Weddington

Date

Considered

3-13-02


*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

RECEIVED

TECHNOLOGY CENTER 1600/2900



Please type a plus sign (+) inside this box



PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 8 of 9

Complete if Known

Application Number	09/995,633
Filing Date	November 29, 2001
First Named Inventor	Dennis JONES
Group Art Unit	1614
Examiner Name	Kevin Weddington
Attorney Docket Number	38545-0014

FEB 20 2002

RECEIVED

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
W	A70	PASQUALI, R., et al. "Clinical aspects of ephedrine in the treatment of obesity", <i>International Journal of Obesity</i> (1993) 17 (Suppl. 1), pp. S65-S68	
	A71	REID, D.P., <i>Chinese Herbal Medicine</i> (1993), pp. 50, 8 and 126-127	
	A72	REYNOLDS, J.E.F., et al., "Ephedrine", <i>MARTINDALE - The Extra Pharmacopoeia</i> (1982), 281 st Edition, pp. 10-12, 671, 678-679	
	A73	SOUTHON, I.W., et al., <i>Chapman & Hall Chemical Database</i> (1989), pp. ???	
	A74	STOKHOLM, K.H., et al., "Lowering of Serum Total T ₃ During a Conventional Slimming Regime", <i>International Journal of Obesity</i> (1983) 7:195-199	
	A75	STREETEN, D.H.P., "The Role of Posture in Idiopathic Oedema", <i>SA Mediese Tydskrif</i> (1975), pp. 462-464	
	A76	STUART, M., "Bitter Orange" and "Ephedra", <i>The Encyclopedia of Herbs and Herbalism</i> (1979), pp. 175, 185	
	A77	TOUBRO, S., et al., "Safety and efficacy of long-term treatment with ephedrine, caffeine and an ephedrine/caffeine mixture", <i>International Journal of Obesity</i> (1993) 17 (Suppl. 1), pp. S69-S72	
	A78	VALLERAND, A.L., "Effects of ephedrine/xanthines on thermogenesis and cold tolerance", <i>International Journal of Obesity</i> (1993) 17 (Suppl. 1), pp. S53-S56	
	A79	WHEATON, T.A., et al., "The Distribution of Tyramine, N-Methyltyramine, Hordenine, Octopamine, and Synephrine in Higher Plants", <i>Lloydia</i> (1970) 33 (No. 2), p. 244-254	
W	A80	"Aurantii fructus immaturus", <i>Herbal Drugs and Phytopharmaceuticals</i> (1994), pp. 93-95	

Examiner
Signature

[Signature]

Date
Considered

3-13-02

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box



PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 065-10031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 9 of 9

Complete if Known

Application Number	09/995,633
Filing Date	November 29, 2001
First Named Inventor	Dennis JONES
Group Art Unit	1614
Examiner Name	Kevin Weddington
Attorney Docket Number	38545-0014

RECEIVED
FEB 20 2002
POST OFFICE CENTER 1600/2900

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
W	A81	YANG, Y.T., et al., "Multiple actions of P-adrenergic agonists on skeletal muscle and adipose tissue", <i>Biochem. J.</i> (1989) 261:1-10	
	A82	MING, O., "Fructus Aurantii Immaturus", <i>Chinese-English Manual of Common-Used in Traditional Chinese Medicine</i> (1989), pp. 348-349	
	A83	ROED, P., et al., "Helsingor-slankepillen", <i>Videnskab OG Praksis</i> (1980), pp. 1491-1495	
	A84	QUER, Dr. P. F., "Efedra Fina (Ephedra major Host)" and "Naranjo Amargo (Citrus aurantium L.)", <i>Plantas Medicinales - El Dioscorides Renovado</i> (1982), pp. 95-97 and 435-438	
W	A85	MALCHOW-MOLLER, A., et al., "Effekten of Helsingor-pillen i behandlingen of adipositas" <i>UGESKR. LIEG.</i> 142/23 (1980), pp. 1496-1499	

Examiner
Signature

Date
Considered

3-13-02

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.